Bacterial co-infections in mucormycosis in severely ill populations: an overlooked and complex challenge

References

1. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19:e405–e421 [View Article] [PubMed]
   [Google Scholar]
2. Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases. Med Mycol 2018; 56:29–43 [View Article] [PubMed]
   [Google Scholar]
3. Cheok KPL, Farrow A, Springell D, O’Reilly M, Morley S et al. Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature. Lancet Infect Dis 2024; 24:e256–e265 [View Article] [PubMed]
   [Google Scholar]
4. Dang J, Goel P, Choi KJ, Massenzio E, Landau MJ et al. Mucormycosis following burn injuries: a systematic review. Burns 2023; 49:15–25 [View Article] [PubMed]
   [Google Scholar]
5. Muthu V, Agarwal R, Rudramurthy SM, Thangaraju D, Shevkani MR et al. Risk factors, mortality, and predictors of survival in COVID-19-associated pulmonary mucormycosis: a multicentre retrospective study from India. Clin Microbiol Infect 2024; 30:368–374 [View Article] [PubMed]
   [Google Scholar]
6. Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe 2022; 3:e543–e552 [View Article] [PubMed]
   [Google Scholar]
7. van de Veerdonk FL, Kolwijck E, Lestrade PPA, Hodiamont CJ, Rijnders BJA et al. Influenza-associated aspergillosis in critically ill patients. Am J Respir Crit Care Med 2017; 196:524–527 [View Article] [PubMed]
   [Google Scholar]
8. Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. High prevalence of putative invasive pulmonary aspergillosis in critically ill COVID-19 patients. SSRN J 2020 [View Article]
   [Google Scholar]
9. Partida-Martinez LP, Groth I, Schmitt I, Richter W, Roth M et al. Burkholderia rhizoxinica sp. nov. and Burkholderia endofungorum sp. nov., bacterial endosymbionts of the plant-pathogenic fungus Rhizopus microsporus. Int J Syst Evol Microbiol 2007; 57:2583–2590 [View Article] [PubMed]
   [Google Scholar]
10. Araldi-Brondolo SJ, Spraker J, Shaffer JP, Woytenko EH, Baltrus DA et al. Bacterial endosymbionts: master modulators of fungal phenotypes. Microbiol Spectr 2017; 5: [View Article] [PubMed]
    [Google Scholar]
11. Tansarli GS, Eschbacher J, Schroeder LK, SenGupta D, Lieberman JA. Mycetohabitans rhizoxinica in patients with rhinocerebral mucormycosis due to Rhizopus microsporus. Mycopathologia 2023; 188:151–153 [View Article] [PubMed]
    [Google Scholar]
12. Yang S, Anikst V, Adamson PC. Endofungal Mycetohabitans rhizoxinica bacteremia associated with Rhizopus microsporus respiratory tract infection. Emerg Infect Dis 2022; 28:2091–2095 [View Article] [PubMed]
    [Google Scholar]
13. Itabangi H, Sephton-Clark PCS, Tamayo DP, Zhou X, Starling GP et al. A bacterial endosymbiont of the fungus Rhizopus microsporus drives phagocyte evasion and opportunistic virulence. Curr Biol 2022; 32:1115–1130 [View Article] [PubMed]
    [Google Scholar]
14. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268–281 [View Article] [PubMed]
    [Google Scholar]
15. World Health Organization WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance; 2024
16. Egge SL, Wurster S, Cho S-Y, Jiang Y, Axell-House DB et al. co-occurrence of gram-negative rods in patients with hematologic malignancy and sinopulmonary mucormycosis. J Fungi 2024; 10:41 [View Article] [PubMed]
    [Google Scholar]
17. Kreitmann L, Helms J, Martin-Loeches I, Salluh J, Poulakou G et al. ICU-acquired infections in immunocompromised patients. Intensive Care Med 2024; 50:332–349 [View Article] [PubMed]
    [Google Scholar]
18. Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006; 44:335–342 [View Article] [PubMed]
    [Google Scholar]
19. Hasan S, Gupta P, Shukla D, Banerjee G. A comparison between potassium hydroxide (KOH) microscopy and culture for the detection of post-COVID-19 rhino-orbital-cerebral mucormycosis. Cureus 2023; 15:e47707 [View Article] [PubMed]
    [Google Scholar]
20. Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR et al. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol 2011; 49:2151–2153 [View Article] [PubMed]
    [Google Scholar]
21. Scherer E, Iriart X, Bellanger AP, Dupont D, Guitard J et al. Quantitative PCR (qPCR) detection of mucorales DNA in bronchoalveolar lavage fluid to diagnose pulmonary mucormycosis. J Clin Microbiol 2018; 56:e00289-18 [View Article] [PubMed]
    [Google Scholar]
22. Millon L, Herbrecht R, Grenouillet F, Morio F, Alanio A et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin Microbiol Infect 2016; 22:810 [View Article] [PubMed]
    [Google Scholar]
23. Davies GE, Thornton CR. Development of a monoclonal antibody and a serodiagnostic lateral-flow device specific to Rhizopus arrhizus (Syn. R. oryzae), the principal global agent of mucormycosis in humans. J Fungi 2022; 8:756 [View Article] [PubMed]
    [Google Scholar]